TBA-7371
- Generic Name
- TBA-7371
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H21N5O3
- CAS Number
- 1494675-86-3
- Unique Ingredient Identifier
- R3T98GBE3C
- Background
TBA-7371 is under investigation in clinical trial NCT04176250 (Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis).
- Associated Conditions
- -
- Associated Therapies
- -
Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Bill & Melinda Gates Medical Research Institute
- Target Recruit Count
- 93
- Registration Number
- NCT04176250
- Locations
- 🇿🇦
TASK, Bellville, Cape Town, South Africa
🇿🇦Perinatal HIV Research Unit (PHRU), Jouberton, North West Province, South Africa
🇿🇦The Aurum Institute, Pretoria, Gauteng, South Africa
A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-06-26
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 74
- Registration Number
- NCT03199339
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath